PGEN - PRECIGEN, INC.
IEX Last Trade
0.7381
-0.007 -0.935%
Share volume: 6,936
Last Updated: Thu 26 Dec 2024 08:17:29 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$0.74
-0.01
-0.93%
Fundamental analysis
8%
Profitability
0%
Dept financing
9%
Liquidity
54%
Performance
3%
Performance
5 Days
5.24%
1 Month
-8.69%
3 Months
-13.92%
6 Months
-49.34%
1 Year
-41.84%
2 Year
-43.91%
Key data
Stock price
$0.74
DAY RANGE
$0.74 - $0.78
52 WEEK RANGE
$0.70 - $1.93
52 WEEK CHANGE
-$44.31
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Helen Sabzevari
Region: US
Website: precigen.com
Employees: 190
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: precigen.com
Employees: 190
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. The company was formerly known as Intrexon Corporation and changed its name to Precigen in January 2020.
Recent news